The background treatment of myasthenia gravis (MG) requires, in some cases, the administration of polyvalent immunoglobulins. US clinicians report the results of a multicentre phase 2 trial comparing the efficacy and safety of subcutaneous versus conventional intravenous immunoglobulin:
- 23 patients with myasthenia with autoantibodies to the acetylcholine receptor participated in the study,
- the trial was conducted over a three-month period, with symptom stability judged by a quantitative MG score,
- the authors recommend adjusting the effective dose of immunoglobulin by an additional 20% to achieve comparable efficacy.
With the same efficacy and tolerance, subcutaneous administration seems to be a promising avenue for immunoglobulin treatment, at least in myasthenia.
